Quarterly ResultMay 5, 2026, 08:38 AM
Disc Medicine Q1 Net Loss $(63.5)M; EPS $(1.65)
AI Summary
Disc Medicine, Inc. reported a net loss of $(63.5) million, or $(1.65) per share, for the first quarter of 2026, significantly wider than the $(34.1) million net loss, or $(1.02) per share, in the same period last year. Total operating expenses increased substantially, driven by higher research and development and selling, general and administrative costs. Despite the losses, the company maintains a strong liquidity position with $730.2 million in cash, cash equivalents, and marketable securities, expected to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $(63.5) million, compared to $(34.1) million in Q1 2025.
- Net loss per share for Q1 2026 was $(1.65), compared to $(1.02) in Q1 2025.
- Total operating expenses increased to $69.5 million in Q1 2026 from $39.9 million in Q1 2025.
- Research and development expenses rose to $45.9 million in Q1 2026 from $27.8 million in Q1 2025.
- Selling, general and administrative expenses increased to $23.6 million in Q1 2026 from $12.2 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $730.2 million as of March 31, 2026.
- Accumulated deficit reached $(573.7) million as of March 31, 2026.
- The company made a $3.0 million milestone payment in Q1 2025 for DISC-0974's Phase 2 clinical trial.
Price Impact
More from IRON